Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
| Autor: | Claudio Marcassa, Maria Teresa Greco, Marzia Lazzari, Clarissa Caldarulo, Simona Finocchi, Oscar Corli |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
cancer pain Time Factors Constipation Narcotic Antagonists medicine.medical_treatment Rome Analgesic Laxative Pharmaceutical Science propensity analysis oxycodone Severity of Illness Index Neoplasms Surveys and Questionnaires Naloxone Drug Discovery medicine Humans Defecation Propensity Score Aged Pain Measurement Retrospective Studies Original Research Pharmacology Drug Design Development and Therapy naloxone business.industry Chronic pain analgesia Middle Aged medicine.disease Analgesics Opioid Drug Combinations Treatment Outcome Tolerability Laxatives Anesthesia Quality of Life Female Chronic Pain medicine.symptom Cancer pain business Oxycodone medicine.drug |
| Zdroj: | Drug Design, Development and Therapy |
| ISSN: | 1177-8881 |
| Popis: | Marzia Lazzari,1 Maria Teresa Greco,2,3 Claudio Marcassa,4 Simona Finocchi,1 Clarissa Caldarulo,1 Oscar Corli2 1Emergency Care, Critical Care Medicine, Pain Medicine and Anesthesiology Department, Tor Vergata Polyclinic, University of Rome, Rome, 2Oncology Department, Pain and Palliative Care Research Unit, Mario Negri IRCCS, 3Department of Clinical Sciences and Community, University of Milan, Milan, 4Cardiology, Fondazione Maugeri IRCCS Veruno, Novara, Italy Background: World Health Organization step III opioids are required to relieve moderate-to-severe cancer pain; constipation is one of the most frequent opioid-induced side effects. A fixed combination, prolonged-release oxycodone/naloxone (OXN), was developed with the aim of reducing opioid-related gastrointestinal side effects. The objective of this study was to compare the efficacy and safety of prolonged-release oxycodone (OXY) alone to OXN in opioid-naïve cancer patients with moderate-to-severe pain. Methods: Propensity analysis was utilized in this observational study, which evaluated the efficacy, safety, and quality of life. Results: Out of the 210 patients recruited, 146 were matched using propensity scores and included in the comparative analysis. In both groups, pain intensity decreased by ≈3 points after 60days, indicating comparable analgesic efficacy. Responder rates were similar between groups. Analgesia was achieved and maintained with similarly low and stable dosages over time (12.0–20.4mg/d for OXY and 11.5–22.0mg/d for OXN). Bowel Function Index (BFI) and laxative use per week improved from baseline at 30days and 60days in OXN recipients (-16, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|